MedPage Today News | Sep 15, 2024
MedPage Today reported on September 13, 2024, that Steward CEO Ralph de la Torre, MD, was a 'no-show' at a hearing despite a subpoena...
Brought to you by RivalSense - an AI tool for monitoring any company.
RivalSense tracks the most important product launches, fundraising news, partnerships, hiring activities, pricing changes, tech news, vendors, corporate filings, media mentions, and other developments of companies you're following π‘
MedPage Today
π medpagetoday.comMedPage Today is a medical news service that covers clinical and policy news, medical meetings, and investigates wrongdoing in medicine. It aims to provide healthcare professionals with reliable information that affects their practices and lives, while also publishing opinions from thought leaders in the healthcare sector.
Updates as of Sep 15, 2024
- MedPage Today reported on September 13, 2024, that Steward CEO Ralph de la Torre, MD, was a 'no-show' at a hearing despite a subpoena.
- On September 10, MedPage Today reported that U.S. House members questioned the FDA's e-cigarette enforcement focus, urging it to target large manufacturers instead of small retailers.
- MedPage Today reports on a study suggesting molnupiravir may offer modest 6-month benefits for high-risk COVID-19 patients.
- A study reported by MedPage Today on September 5, 2024, found no difference in overall survival with versus without bolus 5-fluorouracil in chemotherapy regimens for gastrointestinal cancers, but less toxicity without the bolus.
- A MedPage Today study found that the decline in maternal deaths post-Dobbs was due to a spike in COVID-19 deaths in 2021.
Did you find it useful?
If you liked this report, consider following your own companies of interest. Receive weekly insights directly to your inbox using RivalSense.